Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 1557-1558, 2003; 10.1373/49.9.1557
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (2)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Roelofs, R. W.
Right arrow Articles by Swinkels, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Roelofs, R. W.
Right arrow Articles by Swinkels, D. W.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2003;49:1557-1558.)
© 2003 American Association for Clinical Chemistry, Inc.

Letters to the Editor

PCR-Restriction Fragment Length Polymorphism Method to Detect the X/Y Polymorphism in the Promoter Site of the Mannose-binding Lectin Gene

Rian W. Roelofs1, Tom Sprong2, Jacques B. de Kok2 and Dorine W. Swinkels1,a

1 Department of Clinical Chemistry/564, and
2 Department of Internal Medicine/541, University Medical Centre Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands

aAuthor for correspondence. E-mail D.Swinkels@AKC.umcn.nl.

The first 20% of the full text of this article appears below.


To the Editor:

Mannose-binding lectin (MBL), a pattern-recognition molecule produced by the liver and present in serum, is an important player in the innate immune system. MBL acts by binding various carbohydrate structures on microbial surfaces, after which it activates the complement system via the lectin pathway. In addition, MBL can promote direct opsonophagocytosis of microorganisms and modulate diverse inflammatory mediators (1).

Deficiency of MBL was first identified in association with a common defect of opsonization in children. Additional studies have identified MBL deficiency as a risk factor for diverse infectious diseases (1). In addition, MBL deficiency has been found to be associated with certain autoimmune diseases (1) and, recently, atherosclerosis (2). MBL deficiency is caused by mutations in the coding and promoter regions of the MBL gene, which have a profound effect on plasma concentrations of the MBL protein.

Three point mutations . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Immunol.Home page
W. W. J. van de Sande, A. Fahal, H. Verbrugh, and A. van Belkum
Polymorphisms in Genes Involved in Innate Immunity Predispose Toward Mycetoma Susceptibility
J. Immunol., September 1, 2007; 179(5): 3065 - 3074.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.